Sympatholysis After Neuron-Specific, N-Type, Voltage-Sensitive Calcium Channel Blockade: First Demonstration of N-Channel Function in Humans

Sympatholysis After Neuron-Specific, N-Type, Voltage-Sensitive Calcium Channel Blockade: First Demonstration of N-Channel Function in Humans

SNX-111 is the first neuronal N-type, voltagesensitive calcium channel (VSCC) blocker to enter clinical drug development. Areas of potential therapeutic utility include treatment of nociceptive and neuropathic pain and neuroprotection after ischemic brain injury. The data presented demonstrate that...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cardiovascular pharmacology 1997-09, Vol.30 (3), p.400-403
Hauptverfasser: McGuire, Dawn, Bowersox, Scott, Fellmann, Jere D, Luther, Robert R
Format: Artikel
Sprache:eng
Schlagworte:
Adolescent
Adult
Analgesics
Biological and medical sciences
Blood Pressure - drug effects
Calcium Channel Blockers - adverse effects
Calcium Channel Blockers - pharmacology
Cardiovascular system
Heart Rate - drug effects
Humans
Hypotension, Orthostatic - chemically induced
Injections, Intravenous
Male
Medical sciences
Miscellaneous
Neuropharmacology
omega-Conotoxins
Peptides - adverse effects
Peptides - pharmacology
Pharmacology. Drug treatments
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:SNX-111 is the first neuronal N-type, voltagesensitive calcium channel (VSCC) blocker to enter clinical drug development. Areas of potential therapeutic utility include treatment of nociceptive and neuropathic pain and neuroprotection after ischemic brain injury. The data presented demonstrate that SNX-111 is biologically active in humans and indicate for the first time a neurophysiologic function of N-type VSCCs in humans.
ISSN:0160-2446
1533-4023
DOI:10.1097/00005344-199709000-00019